People · Operator
Named in public records as an officer, director or promoter · active 2021–2022 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Camp4 Therapeutics Corp | — | Biotechnology | Series D+ | $179.6M | $2.2B | 2022 |
| Garuda Therapeutics, Inc. | — | Biotechnology | Series C | $158.0M | $380.2M | 2021 |
Shaan I Gandhi at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Shaan I Gandhi on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Carl Gordon | 1 | 24 |
| Amir Nashat | 1 | 14 |
| Michael Higgins | 1 | 9 |
| Andrew J. Schwab | 1 | 7 |
| Jorge Conde | 1 | 4 |
| Raymond Kelleher | 1 | 4 |
| Shaan Gandhi | 1 | 4 |
| Eric Aguiar | 1 | 3 |
| Steve Liapis | 1 | 3 |
| Paula Ragan | 1 | 3 |
| ANN BARBIER | 1 | 2 |
| Adam Craig | 1 | 2 |
| David Kirske | 1 | 2 |
| Andy Schwab | 1 | 2 |
| JOSH MANDEL-BREHM | 1 | 1 |
| ALFICA SEHGAL | 1 | 1 |
| MICHELLE GATES | 1 | 1 |
| KELLY GOLD | 1 | 1 |
| DAVID BUMCROT | 1 | 1 |
| JAMES J. BOYLAN | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.